France Reports First Human Death Linked to Shamonda Virus

OPA WIRE, Oct 22 (OPA) — French health officials in Lyon confirmed the death of a patient infected with the Shamonda virus, marking the first documented human case of the pathogen. The virus, which primarily affects cattle, sheep, and goats, was previously considered non-transmissible to humans. Government representatives stated that the patient’s severe immunosuppression likely rendered them uniquely vulnerable, characterizing the incident as an exceptional case rather than a sign of broader human-to-human transmission.

Preliminary investigations suggest the patient contracted the virus through the bite of a biting midge, the same insect responsible for spreading the pathogen among livestock. Since its initial identification in Nigeria in the 1960s, the virus has been documented in Africa and Japan. While cattle serve as the primary host, exhibiting symptoms such as fever and reduced milk production, the virus has recently expanded its reach, with a new variant, Shamonda-Europe, detected across several European nations including Switzerland, Germany, and Spain.

Experts caution against alarm, emphasizing the specific health profile of the deceased. Ben Brennan, a professor of virology at the University of Glasgow, noted that while the finding is scientifically significant, it remains unclear to what extent the virus directly contributed to the patient's death given their pre-existing conditions. David Roiz, a scientist at the Institute for Game and Wildlife Research in Spain, added that sporadic human infections from mammal-borne viruses are not unexpected in a globalized environment, though continued vigilance is required.

As no vaccine currently exists for the Shamonda virus, control efforts remain focused on the use of insecticides and repellents to manage midge populations. Spanish agricultural authorities have confirmed the circulation of two genetically distinct forms of the virus, Type 1 and Type 2, across 37 French provinces as of early September. Health agencies across Europe continue to monitor the situation, maintaining that current evidence does not suggest a widespread threat to the general population.